Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02997319 · ClinicalTrials.gov registry record
Shift Work, Heredity, Insulin, and Food Timing Study
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 365
- Enrollment target
NCT02997319: Completed study, sponsored by Massachusetts General Hospital.
NCT02997319 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 365 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02997319 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 365 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether night time eating that coincides with elevated endogenous melatonin impairs glucose tolerance, particularly in carriers of the MTNR1B risk allele.
Primary Outcome
Investigators will measure insulin and glucose levels for 120 minutes at day time and night time visits, and compare them by genotype at selected loci.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2017-02-24 |
| Est. Completion | 2021-05-08 |
What the finished NCT02997319 record still lists
NCT02997319 is an observational study that tracks outcomes without assigning an intervention. The registered 365 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02997319 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02997319 about?
NCT02997319 is a clinical study titled "Shift Work, Heredity, Insulin, and Food Timing Study". The purpose of this study is to determine whether night time eating that coincides with elevated endogenous melatonin impairs glucose tolerance, particularly in carriers of the MTNR1B risk allele.
What is the current status of trial NCT02997319?
This trial is currently completed. The enrollment target is 365 participants. The study started on 2017-02-24. Estimated completion is 2021-05-08.
Who is sponsoring clinical trial NCT02997319?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04049604 · 365 participants · NA
IDENTIFY Study: Natural History of Maternal Neoplasia
- NCT05065840 · 365 participants · NA
Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study
- NCT05303519 · 365 participants · Phase 3
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- NCT05592626 · 365 participants · Phase 1
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI